Mebendazole 100mg, 6 Tablets — TM Vermoks

Vermox (Mebendazole)

Vermox is a pharmaceutical-grade formulation of Mebendazole produced by Janssen (a Johnson & Johnson company). This product listing features a complete box of 6 tablets, an ideal and standardized quantity utilized for targeted metabolic, oncological, and anti-parasitic research protocols.

General Pharmaceutical & Manufacturer Information

• Brand Name: Vermox (Вермокс)
• Active Ingredient: Mebendazole (Мебендазол)
• Dosage: 100 mg of Mebendazole per tablet
• Other Components (Excipients): Sodium saccharin and other excipients
• Package Size: 1 Pack (6 tablets)
• CAS Number: 31431-39-7
• Molecular Formula: C16H13N3O3
• Form: Oral tablets
• Manufacturer: Janssen-Cilag (Janssen Pharmaceutica NV, Belgium / licensed division)

Primary Therapeutic Focus: Oncology Prevention & Adjuvant Research

While traditionally classified as a broad-spectrum anthelmintic agent, Mebendazole is highly celebrated in modern translational medicine and oncology research. Due to its structural and functional properties, it is actively studied as an effective, repurposed anti-cancer drug.

• Microtubule Disruption: Mebendazole binds to the colchicine-binding site of β-tubulin, preventing its polymerization. In cancer cells, this disrupts spindle formation during mitosis, arresting the cell cycle at the G2/M phase and leading to selective mitotic catastrophe and cell death (apoptosis).
• Angiogenesis Inhibition: Emerging oncological studies indicate that Mebendazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) signaling, suppressing tumor angiogenesis (the formation of new blood vessels) and cutting off the nutrient supply to tumor microenvironments.
• Inhibition of Cancer Stem Cells (CSCs) and Metastasis: It has been shown to target highly resistant cancer stem cell subpopulations in various aggressive tumor types, such as glioblastoma, colorectal cancer, and breast cancer, helping to suppress tumor initiation, recurrence, and metastatic spread.
• Synergy with Standard Chemotherapy: In preclinical studies, Mebendazole demonstrates remarkable synergy when evaluated alongside conventional chemotherapies, radiotherapy, and metabolic therapeutic interventions.

Anti-Aging & Longevity Properties (Geroprotection & Senolysis)

In the context of life-extension research, Mebendazole is evaluated for its systemic cellular pathways.

• Inhibition of the Hedgehog Signaling Pathway: Dysregulation of Hedgehog signaling is deeply linked to cellular senescence, tissue fibrosis, and age-associated stem cell exhaustion. Mebendazole acts as a powerful inhibitor of this pathway, helping preserve tissue homeostasis.
• Senomorphic Activity: By modulating key transcription factors and metabolic pathways, Mebendazole assists in suppressing systemic inflammatory signaling (mitigating inflammaging), which decelerates the progressive aging of surrounding healthy tissues.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.